Clobenpropit: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
m →‎See also: adjust link
m refine |legal status= (via JWB)
Line 6: Line 6:
| tradename =
| tradename =
| pregnancy_category =
| pregnancy_category =
| legal_status = Investigative new drug (not yet approved by the FDA)
| legal_US = Investigative new drug
| routes_of_administration =
| routes_of_administration =



Revision as of 16:12, 25 February 2017

Clobenpropit
Clinical data
ATC code
  • none
Legal status
Legal status
  • US: Investigative new drug
Identifiers
  • N'-[(4-chlorophenyl)methyl]-1-[3-(3H-imidazol-4-yl)propylsulfanyl]formamidine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H17ClN4S
Molar mass308.83 g/mol g·mol−1
3D model (JSmol)
  • C1=CC(=CC=C1CN=C(N)SCCCC2=CN=CN2)Cl

Clobenpropit is a histamine H3 receptor antagonist.[1] It has neuroprotective effects via stimulation of GABA release in the brain.[2]

See also

References

  1. ^ Sahlholm K, Nilsson J, Marcellino D, Fuxe K, Arhem P (2007). "The human histamine H3 receptor couples to GIRK channels in Xenopus oocytes". European Journal of Pharmacology. 567 (3): 206–210. doi:10.1016/j.ejphar.2007.04.032. PMID 17537431.
  2. ^ Dai H, Fu Q, Shen Y, Hu W, Zhang Z, Timmerman H, Leurs R, Chen Z (2007). "The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons". European Journal of Pharmacology. 563 (1–3): 117–123. doi:10.1016/j.ejphar.2007.01.069. PMID 17350613.